Hepatic Insufficiency

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)

A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems

A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations

Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies

A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems

A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function

A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants

A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)

A Study of LY3437943 in Participants With Impaired and Normal Liver Function

Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)

Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants